Arbutus Biopharma (ABUS) EBIT (2013 - 2026)
Arbutus Biopharma (ABUS) posted EBIT of $168.9 million for Q1 2026, up 3292.97% sequentially from -$5.3 million in Q4 2025, and up 757.26% YoY from $19.7 million in Q1 2025.
Arbutus Biopharma (ABUS) EBIT (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported EBIT for 14 years, with the latest figure at $168.9 million in Q1 2026.
- Quarterly EBIT rose 757.26% year-over-year to $168.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $156.4 million (up 289.28% YoY) and the FY2025 annual result came in at -$38.2 million, up 50.0% from the prior year.
- EBIT advanced to $168.9 million in Q1 2026 per ABUS's latest filing, from -$5.3 million in the prior quarter.
- Over five years, EBIT peaked at $168.9 million in Q1 2026 and troughed at -$25.7 million in Q1 2025.
- A 5-year average of -$5.2 million and a median of -$17.8 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2026: EBIT tumbled 58.68% in 2023, then surged 757.26% in 2026.
- Over 5 years, EBIT stood at -$22.6 million in 2022, then increased by 8.04% to -$20.7 million in 2023, then jumped by 32.84% to -$13.9 million in 2024, then jumped by 62.03% to -$5.3 million in 2025, then soared by 3292.97% to $168.9 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered $168.9 million, -$5.3 million, and -$8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -5.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.96 Mn |
| Mar 31, 2026 | 168.91 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Sep 30, 2025 | -8.66 Mn |
| Jun 30, 2025 | 1.49 Mn |
| Mar 31, 2025 | -25.70 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Sep 30, 2024 | -21.44 Mn |
| Jun 30, 2024 | -21.58 Mn |
| Mar 31, 2024 | -19.36 Mn |
| Dec 31, 2023 | -20.75 Mn |
| Sep 30, 2023 | -21.56 Mn |
| Jun 30, 2023 | -18.39 Mn |
| Mar 31, 2023 | -17.41 Mn |
| Dec 31, 2022 | -22.56 Mn |
| Sep 30, 2022 | -17.81 Mn |
| Jun 30, 2022 | -14.11 Mn |
| Mar 31, 2022 | -10.97 Mn |
| Dec 31, 2021 | -20.80 Mn |
| Sep 30, 2021 | -18.41 Mn |